Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by FarmerBetsyon Nov 22, 2023 4:37pm
160 Views
Post# 35749140

RE:RE:Elliot, Ouch to the many haters could be a hate crime !

RE:RE:Elliot, Ouch to the many haters could be a hate crime !For sure if you back Roche up 6-7 years ago with Gantenermab Phase 1, but look at the most recent trials not only Prothena and Acumen you won't just find 8 healthy patients. Prothena the latest filed an IND for an Alzheimers trial got it and the next month were recruiting.  Included are alzheimers patients which makes total sense. Bottombroker why don't you and Retired Cop who post one after the other cut the foolishness? After how many years with these charactors do you think you are with an ethical bunch who has all shareholders interest?
<< Previous
Bullboard Posts
Next >>